Ibrance, also known as palbociclib, is a Pfizer breast cancer drug currently in phase III trials. Although the trial faced delays due to efficacy issues, results have shown improvements in Progression-Free Survival (PFS). The drug is for postmenopausal women with metastic cancer that meets a specific profile. Ibrance was fast-tracked for FDA approval in February of this year under a program that gives patients access to promising investigational drugs during late stage clinical trials. Read further by clicking here or here.
“The results of this trial are especially important because they help us understand the potential of IBRANCE to improve outcomes in patients with this difficult to treat cancer. We’re gratified to be able to stop the trial early and are engaging in discussions with health authorities regarding a regulatory path forward,” says Dr. Mace Rothenberg, the chief medical officer and senior vice president of Clinical Development and Medical Affairs of Pfizer Oncology.
